Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1
- PMID: 11085537
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1
Abstract
Treatment of metastatic prostate cancer with androgen-ablation often elicits dramatic tumor regressions, but the response is rarely complete, making clinical recurrence inevitable with time. To gain insight into therapy-related progression, changes in gene expression that occurred following androgen-deprivation of an androgen-dependent prostate tumor xenograft, CWR22, and the emergence of an androgen-independent tumor, CWR22-R, were monitored using microarray analysis. Androgen-deprivation resulted in growth arrest of CWR22 cells, as evidenced by decreased expression of genes encoding cell cycle components and basal cell metabolism, respiration and transcription, and the induced expression of putative negative regulatory genes that may act to sustain cells in a nonproliferative state. Evolution of androgen-independent growth and proliferation, represented by CWR22-R, was associated with a reentry into active cell cycle and the up-regulation of several genes that were expressed at low levels or absent in the androgen-dependent tumor. Androgen repletion to mice bearing androgen-independent CWR22-R tumors induced, augmented, or repressed the expression of a number of genes. Expression of two of these genes, the calcium-binding protein S100P and the FK-506-binding protein FKBP51, was decreased following androgen-deprivation, subsequently reexpressed in CWR22-R at levels comparable with CWR22, and elevated further upon treatment with androgens. The dysregulated behavior of these genes is analogous to other androgen-dependent genes, e.g., prostate-specific antigen and human kallikrein 2, which are commonly reexpressed in androgen-independent disease in the absence of androgens. Other androgen-responsive genes whose expression decreased during androgen-deprivation and whose expression remained decreased in CWR22 were also identified in CWR22-R. These results imply that evolution to androgen-independence is due, in part, to reactivation of the androgen-response pathway in the absence of androgens, but that this reactivation is probably incomplete.
Similar articles
-
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.Mol Carcinog. 2004 Nov;41(3):150-63. doi: 10.1002/mc.20051. Mol Carcinog. 2004. PMID: 15390081
-
Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.Cancer Res. 1998 Dec 15;58(24):5718-24. Cancer Res. 1998. PMID: 9865729
-
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.Cancer Res. 2002 Nov 15;62(22):6606-14. Cancer Res. 2002. PMID: 12438256
-
Androgen-regulated gene expression in prostate cancer.Semin Cancer Biol. 1997 Feb;8(1):29-36. doi: 10.1006/scbi.1997.0050. Semin Cancer Biol. 1997. PMID: 9299579 Review.
-
The importance of steroid hormones in prostate cancer.Cancer Surv. 1992;14:113-30. Cancer Surv. 1992. PMID: 1423327 Review.
Cited by
-
Basic science of hormonal therapy for prostate cancer.Rev Urol. 2001;3 Suppl 3(Suppl 3):S15-22. Rev Urol. 2001. PMID: 16986004 Free PMC article.
-
Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer.Cancers (Basel). 2018 Sep 25;10(10):352. doi: 10.3390/cancers10100352. Cancers (Basel). 2018. PMID: 30257470 Free PMC article. Review.
-
Heterodimeric interaction and interfaces of S100A1 and S100P.Biochem J. 2004 Aug 15;382(Pt 1):375-83. doi: 10.1042/BJ20040142. Biochem J. 2004. PMID: 15171681 Free PMC article.
-
S100P: a novel therapeutic target for cancer.Amino Acids. 2011 Oct;41(4):893-9. doi: 10.1007/s00726-010-0496-4. Epub 2010 May 28. Amino Acids. 2011. PMID: 20509035 Free PMC article. Review.
-
Prostate cancer - a biomarker perspective.Front Endocrinol (Lausanne). 2012 May 29;3:72. doi: 10.3389/fendo.2012.00072. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22661971 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous